Paper Details

  1. Home
  2. Paper Details

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.

Author: AugustineCarole, BrewerClaudette, HeftingNanco, HobartMary, McQuadeRobert D, SanchezRaymond, SkubanAleksandar, ZhangPeter

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Adjunctive brexpiprazole (2 mg/d) improved Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6 compared to placebo in patients with major depressive disorder (MDD) and inadequate response to antidepressants.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs. METHODS: Outpatients with inadequate response to 1-3 ADTs during their current depressive episode...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4088/JCP.17m12058

データ提供：米国国立医学図書館（NLM）

Brexpiprazole: A Potential Booster for Depression Treatment

Major depressive disorder (MDD) can feel like a deep and isolating desert, leaving individuals feeling lost and overwhelmed. This study explores the potential of brexpiprazole as an adjunctive treatment for adults with MDD who have had an inadequate response to antidepressants. The researchers conducted a randomized, placebo-controlled trial to investigate the efficacy and safety of brexpiprazole as an adjunct to antidepressant treatment.

Brexpiprazole: A Potential Ally in Combating Depression

The study found that [研究結果]. This finding suggests that [社会的な意義] and offers a potential new approach for managing MDD in individuals who have not fully responded to antidepressant treatment.

Navigating the Treatment of MDD

The research provides valuable insights for patients and clinicians managing MDD. The study found that [研究結果]. It is important to consult with a healthcare provider to discuss potential treatment options and to consider the role of adjunctive therapies, like brexpiprazole, in managing MDD.

Dr.Camel's Conclusion

This study provides a glimmer of hope in the desert of depression treatment, highlighting the potential of brexpiprazole as an effective adjunctive therapy for adults with MDD who have not fully responded to antidepressants. The findings underscore the importance of personalized treatment approaches and the need for further research to optimize treatment strategies and to improve long-term outcomes for individuals with MDD.
Date :
  1. Date Completed 2019-09-30
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

29873953

DOI: Digital Object Identifier

10.4088/JCP.17m12058

Related Literature

Article Analysis
・Side Effects of brexpiprazole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.